This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Alflutinib
- DrugBank Accession Number
- DB16087
- Background
Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Alflutinib (DB16087)
- Weight
- Average: 568.605
Monoisotopic: 568.252206759 - Chemical Formula
- C28H31F3N8O2
- Synonyms
- Not Available
- External IDs
- AST-2818
- AST2818
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A49A7A5YN4
- CAS number
- 1869057-83-9
- InChI Key
- GHKOONMJXNWOIW-UHFFFAOYSA-N
- InChI
- InChI=1S/C28H31F3N8O2/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35)
- IUPAC Name
- N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide
- SMILES
- CN(C)CCN(C)C1=NC(OCC(F)(F)F)=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C1NC(=O)C=C
References
- General References
- Not Available
- External Links
- ChemSpider
- 81367235
- ChEMBL
- CHEMBL4297258
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Advanced Non-Small Cell Lung Cancer (NSCLC) / EGFR Exon 20 Mutations / Metastatic Non-Small Cell Lung Cancer 1 2 Enrolling by Invitation Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Not Yet Recruiting Treatment Adenocarcinoma of the Lung 1 2 Not Yet Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Recruiting Treatment EGFR G719X / EGFR L861Q / EGFR S768I / Non-Small Cell Lung Cancer (NSCLC) 1 2 Recruiting Treatment Multiple Primary Lung Cancers 1 2 Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 5 2 Unknown Status Treatment Advanced NSCLC Patients With T790M 1 2, 3 Not Yet Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 1 Completed Other Healthy Male Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00867 mg/mL ALOGPS logP 4.59 ALOGPS logP 5.41 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) 12.17 Chemaxon pKa (Strongest Basic) 8.75 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 100.44 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 154.24 m3·mol-1 Chemaxon Polarizability 57.11 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:04 / Updated at December 20, 2020 03:36